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Abstract
Background: Systemic chemotherapy combined with steroids used as prophylactic antiemetics have been reported
to induce immunosuppression. Further, herpes simplex virus-1 (HSV-1) infection has been reported to occur in patients
with small cell carcinomas after chemoradiotherapy that includes brain irradiation. Here, we report a case of HSV-1
encephalitis that occurred in a patient undergoing chemoradiotherapy for advanced esophageal cancer.
Case presentation: A 77-year-old woman received chemoradiotherapy (5-fluorouracil, 700 mg/m2; cisplatin,
70 mg/m2; and radiotherapy, 60 Gy in total) for stage III esophageal cancer. The total radiation dose was
administered concurrently with the first two courses of chemotherapy, together with dexamethasone as a
prophylactic antiemetic. Two days before completion of the fourth course of chemotherapy, the patient developed
acute neurological symptoms of disorientation, clouding of consciousness, and fever. T2-weighted magnetic resonance
imaging showed a high intensity area in the bilateral temporal lobes and insular cortex. Furthermore, DNA PCR testing
of cerebrospinal fluid showed clear positivity for HSV-1 DNA, and the patient was diagnosed with herpetic encephalitis.
Intravenous administration of acyclovir for 3 weeks led to gradual improvement of consciousness, and the patient was
able to respond to verbal cues.
Conclusion: In advanced esophageal cancer patients, standard treatment involves chemoradiotherapy and
surgery. However, primary infection with or reactivation of endogenous latent HSV-1 in the brain cortex
during chemoradiotherapy combined with administration of a steroid may compromise the benefits of
treatment.
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Background
Esophageal cancer patients are very likely to undergo
chemotherapy and radiotherapy as definitive chemora-
diotherapy for advanced esophageal cancer is a widely
accepted standard treatment, with a combination of
5-fluorouracil (5-FU) and cisplatin with concurrent
irradiation (50–60 Gy total dose) being a standard
regimen [1, 2].
Herpes simplex virus (HSV) is a well-characterized
double-stranded DNA virus that can latently infect the
spinal, trigeminal, and sacral cord ganglia. One subtype
of the virus, HSV type 1 (HSV-1) commonly infects the
trigeminal ganglia and may reactivate and spread from
there to result in herpes labialis, stomatitis, keratitis, or
encephalitis.
Herpes simplex encephalitis (HSE) accounts for 10–20 %
of encephalitis cases and is particularly noted in cases of
sporadic encephalitis, the annual morbidity rate of which is
2–4 individuals per million [3–5]. HSV-1 is responsible for
95 % of all cases of HSE, and it is estimated that
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approximately 70–80 % of these occurrences are caused by
reactivation of latent virus or re-infection, while the
remaining cases are due to primary infection. Fatigue,
trauma, and stress that weaken the host’s immune system
can lead to reactivation of the latent virus. Moreover, sys-
temic chemotherapy along with steroids used as prophylac-
tic antiemetics may also induce immunosuppression.
Only a few case reports of HSE following chemotherapy
or steroid therapy in cancer patients exist [6]. Herein, we
report a case of HSV-1 encephalitis that occurred during
chemoradiotherapy in a patient with advanced esophageal
cancer.
Case presentation
A 77-year-old woman had been suffering from dys-
phagia for 2 months prior to hospitalization. She was
diagnosed with stage III esophageal cancer at a local
hospital and was referred to our hospital for further
treatment. Esophagogastroduodenoscopy showed a type 2
tumor in the lower intrathoracic esophagus. Enhanced
computed tomography showed wall thickening and ambi-
ent lymphadenopathy. She received chemoradiotherapy
(5-FU, 700 mg/m2; cisplatin, 70 mg/m2; and radiotherapy,
60 Gy in total) every 28 days. The total irradiation dose to
the mediastinum was administered concomitantly with
two courses of chemotherapy, combined with dexametha-
sone as a prophylactic antiemetic. Partial remission after
two courses of chemoradiotherapy was achieved and the
residual esophageal tumor was minimal.
However, 2 days before completion of the fourth course
of chemotherapy, the patient developed acute neurological
symptoms of disorientation, clouding of consciousness,
and fever. At the onset, leukocyte count was 2020, and the
lymphocyte count had decreased to 120/mm3. Serum
squamous cell carcinoma antigen was 1.9 ng/mL and the
remaining serological parameters were within normal
ranges. Blood culture results were negative, and chest and
abdominal radiography findings were unremarkable.
A computed tomography (CT) scan of the brain at the
onset of symptoms revealed only multiple small low-
density areas dispersed around a cerebral hemisphere,
which were remnants of an earlier cerebral infarction.
Coronal T2-weighted magnetic resonance imaging
(MRI) of the brain revealed bilateral high intensity areas
in the temporal lobes. Diffusion-weighted imaging re-
vealed enhanced high intensity areas corresponding to
the bilateral temporal lobes (Fig. 1). These findings
strongly suggested acute encephalitis. An electroenceph-
alogram showed a diffuse sharp wave–slow wave com-
position wave (Fig. 2).
Examination of cerebrospinal fluid showed no occur-
rence of pleocytosis of mononuclear cells, with only two
monocytes and eight erythrocytes being identified in
3 μL of CSF. Furthermore, CSF glucose and protein were
normal. However, the DNA PCR consensus herpes test
showed clear positivity for HSV-1 DNA. Based on these
findings, we arrived at a diagnosis of acute HSV-1 en-
cephalitis by endogenous viral reactivation in an im-
munocompromised patient.
With intravenous administration of acyclovir for 3
weeks, the patient’s state of consciousness gradually
improved, as she regained the ability to understand and
respond to simple instructions. She was subsequently
transferred to another hospital, where she is currently
being treated. To date, her cancer has not recurred and,
although she is confined to a wheelchair and fed by tube,
she remains capable of responding to simple verbal cues.
Discussion
The overall annual incidence of HSE is estimated at 2–4
individuals per million. An immunosuppressive state is
thought to contribute to reactivation of latent HSV, and
Fig. 1 Magnetic resonance imaging of the brain upon onset of symptoms. a Coronal T2-weighted magnetic resonance imaging of the brain revealed
high intensity areas bilaterally in the temporal lobes. b Diffusion-weighted imaging revealed enhanced high intensity areas corresponding to the bilateral
temporal lobes
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yet it is not expected to affect the incidence rate of HSE,
although the severity of this disease is likely to be worse
in the immunocompromised [7]. However, comorbidities
of cancer, chemotherapy, radiotherapy, steroid therapy,
and other disorders are known to elevate the incidence
of HSE by decreasing cell-mediated immunity [5, 8].
Chemoradiotherapy for esophageal cancer is indicated
for patients with resectable cancer who cannot tolerate
surgery and those with unresectable stage T4 cancer or
lymph node metastasis that is confined to one particular
area. A phase II clinical study on the standard chemora-
diotherapy regimen (FP therapy [5-FU, 1,000 mg/m2;
cisplatin, 75 mg/m2] plus radiotherapy, 50.4 Gy) was
conducted in patients with esophageal cancer at clinical
stages II/III (excluding those with stage T4 cancer) in
Japan [2]. Despite the favorable outcomes observed
(complete response rate of 70 % and a 3-year survival
rate of 63.8 %), acute toxicity was slightly increased. The
toxicity of chemotherapy, especially cisplatin, includes
nausea and vomiting in the acute phase. When such
highly emetogenic drugs are administered, it is recom-
mended that the following three-drug combination be in-
cluded: oral administration of the neurokinin -1 receptor
antagonist aprepitant at 125 mg, a 5-hydroxytryptamine-3
receptor antagonist, and dexamethasone at 12 mg [9–11].
In the present case, the patient received four courses
of FP therapy and radiotherapy to the mediastinum.
Additionally, steroids were also administered to prevent
emesis. While systemic chemotherapy has been reported
to induce suppression of systemic immunity, it is as-
sumed that administration of steroids further contrib-
uted to the patient’s immunosuppression. Consistent
with this, a decreased peripheral lymphocyte count was
also observed.
Graber et al. summarized prior reports of cancer patients
subsequently diagnosed with HSE, including patients from
their own academic cancer center over a 12-year period.
He reported that 19 cancer patients receiving chemother-
apy developed HSE in the past 12 years [6], indicating a
higher than expected incidence of HSE in this population.
The cohort included 11 patients with brain tumors, three
with lung cancer, two with breast cancer and one patient
each with malignant lymphoma, multiple myeloma and
renal cancer. Patients received various chemotherapeutic
agents, and brain radiation was concomitantly administered
in 13 of these individuals. Of the total cohort, two patients
Fig. 2 Electroencephalogram upon onset of symptoms. An electroencephalogram showed a diffuse sharp wave–slow wave composition wave
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survived and 15 died of herpes encephalitis. Follow up data
were incomplete for the remaining two individuals. There
have been no reports of this disease occurring during
chemotherapy for esophageal cancer, and the present
case is thus the first reported case. This patient re-
ceived systemic chemotherapy and directed radiation to
the mediastinum; however, the specific relationship be-
tween development of HSE and mediastinal radiation
remains unclear.
Because HSE is generally difficult to diagnose in cancer
patients, it is assumed that there are patients who remain
without a definitive diagnosis and experience unfavorable
outcomes. The disease is often difficult to differentiate
from brain metastasis, paraneoplastic syndrome, and cere-
bral infarction as a manifestation of Trousseau’s syndrome
[12, 13]. Although fever, recurrent syncopal attacks and
disorientation were observed in the present case, a clinical
diagnosis was difficult to make. When cancer patients
experience progressive neurological symptoms with evi-
dence of inflammation, it is prudent to actively suspect a
comorbidity of HSE, with brain metastasis also taken into
consideration.
Many studies have been conducted regarding various
diagnostic procedures for this disease [12, 13]. MRI de-
picts edematous changes due to inflammation as normal
intensity areas on T1-weighted images and high intensity
areas on T2-weighted images in the cortices of the bilat-
eral temporal lobes, white matter, and insular cortex.
MRI should allow for earlier diagnosis than a CT scan.
In the present case, although no apparent finding was
obtained by CT scan, MRI revealed mildly high intensity
areas in the medial cortices of the bilateral temporal
lobes and insular cortex on fluid-attenuated inversion
recovery images.
The examination of cerebrospinal fluid of HSE patients
generally reveals elevated cerebrospinal fluid pressure,
cytosis with lymphocytic predominance, and increased
protein. The glucose concentration is often normal. Eryth-
rocytes or xanthochromia may be also detected in some
cases [14].
When HSV-DNA is detected in the cerebrospinal fluid
via PCR, a definitive diagnosis can be made; however, a
negative result does not rule out HSE [15–17]. In the
present case, PCR was indeed positive for HSV-DNA,
leading to the definitive diagnosis.
Electroencephalograms show abnormalities in almost all
cases of HSE. Focal abnormalities are found in many cases,
whereas periodic lateralized epileptic discharges, which are
considered to be relatively characteristic to HSE, are found
in approximately 30 % of cases. The present case showed a
diffuse sharp-and-slow-wave complex.
Since the advent of the use of acyclovir for the treat-
ment of HSE, mortality has markedly decreased from 70
to 7.1–28 % [4–6, 18]. As a general guideline, acyclovir
is intravenously infused at a dose of 10 mg/kg three
times a day for 14 days or more [19, 20]. For the treat-
ment of convulsive seizures and cerebral edema, diaze-
pam, midazolam, phenytoin, or other agents are used. In
order to treat cerebral edema, glyceol, mannitol, and ste-
roids are recommended. The mechanisms of action of
corticosteroids are assumed to include the reduction of
cerebral edema and the inhibition of secretion of proin-
flammatory cytokines. In the present case, while acyclo-
vir was administered for 3 weeks, the patient received
methylprednisolone for 3 days at a dose of 1,000 mg/day
to prevent cerebral edema and phenobarbital for 4 weeks
at a dose of 100 mg/day to prevent convulsions. Al-
though the prognosis of this disease has traditionally
been extremely poor, our patient recovered. She was
subsequently transferred to another hospital, where she
is currently being treated.
Conclusions
Any esophageal cancer patient who undergoes chemora-
diotherapy and has subsequent neurologic decline should
be evaluated for HSE. Furthermore, patients undergoing
chemotherapy should be monitored, given the possibility
of latent HSV-1 reactivation. When HSE is suspected, we
recommend that antiviral therapy commence immedi-
ately, as this may prove lifesaving while the diagnosis is
being confirmed.
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